Health

Public and private health converge in the exploitation of data

Juan Jose Camacho Parejo; José Ramón Luis-Yagüe; Elena Andradas; Jose Luis Alfonso Sanchez; and Jose Javier Castrodeza.

In 2020, the Public health It meant an expense of 80 euros per inhabitant in Spain, while for healthcare medicine it was 1,487 euros, and spending on medical products amounted to 535 euros per inhabitant. This extremely low investment in Public Health inevitably causes the public-private partnerships be minor. In fact, the interests of companies are often at odds with the objectives of said alliances in Public Health, “an unappetizing prey”. In this context, experts in this field pursue a paradigm shift so that this relationship is more enriching for all parties and find in the clinical data the most valuable transformation tool for the nearest future.

Discussion table at the Conference ‘Present and future of Public Health’, in full.

“The datain a space of legal security, are part by nature of the Epidemiology. If we are able to reach agreements with the different actors, both public and private, that common data management will bring benefits to all of us, a extraordinary paradigm shift”, has pointed out Juan Jose CamachoGeneral Director of Public Health of the Ministry of Health of Castilla-La Mancha, at the conference ‘Present and future of Public Health’ organized by Medical Writing.

“The information has an incalculable value, so we have to know how to handle it with the public and private part,” he added. Jose Javier Castrodeza, former Secretary General of Health of the Ministry of Health, who moderated the panel of the event, which has had the collaboration of GSK, MSD, Novo Nordisk and Sanofi. The public-private relationship has to change “because it does not give more of itself” and, for this necessary leap, Camacho explained, Public Health must “break with shyness” and respect two fundamental pillars for this relationship to prosper, always based on legal guarantees and with the knowledge of the users. On the one hand, transparency and legal certainty. On the other, to be absolutely certain that Public health is a public service.

Juan José Camacho Parejo, General Director of Public Health of the Ministry of Health of Castilla-La Mancha.


Null public-private collaboration in Public Health

The role of private health and health insurance seems to be, according to Jose Luis Alfonso SanchezProfessor of Preventive Medicine and Public Health at the University of Valencia, increasingly important for the overall functioning of the Spanish health system. “To the endemic problems of saturation and long waiting lists in the public health service, the imbalances caused by the long months of restrictions caused by the Covid-19 pandemic have been added,” the professor has developed.

José Luis Alfonso Sánchez, Professor of Preventive Medicine and Public Health at the University of Valencia.

Faced with this panorama, he stated that the Spanish have seen in Health insurance the ideal solution to mitigate deficiencies presented by the public system. “And this, in turn, benefits from a progressive decongestion thanks to the alternative service provided by private health”, he continued, lamenting that the public-private alliance in Public Health is practically nil given the low spending in this area. In addition, it has continued, the collaboration is limited to drug research and other health activities.

José Ramón Luis-Yagüe, director of the Department of Relations with the Autonomous Communities of the National Business Association of the Pharmaceutical Industry (Farmaindustria).

For his part, Jose Ramon Luis-Yagüedirector of the Department of Relations with the Autonomous Communities of the National Business Association of the Pharmaceutical Industry (Farmaindustria), which declares itself “strong defender” of this collaboration, has ensured that the industry is part of the National Health System (SNS). “We are not suppliers”, she stressed, informing that Farmaindustria has signed 380 collaboration agreements.

José Javier Castrodeza, former General Secretary of Health of the Ministry of Health.

In the words of Luis-Yagüe, the pandemic has revealed the weakness of Public Health and Spain’s dependence on third-party markets. “The SNS problem is budget insufficiency and this is solely a political decision. We have to look at the results in Health; they are spectacular. In the last 10 years, life expectancy has increased by 73 percent of life expectancy in developed countries thanks to medicines, ”he has estimated.

Instruments for public-private collaboration

As a subject matter expert, Elena Andradas, General Director of Public Health of the Madrid Ministry of Health, has indicated that public-private collaboration made available to Public Administrations is once again at the center of the agenda. Public bidding, consortiums, agreements and subsidies are the instruments that the legal system contemplates.

Elena Andradas, General Director of Public Health of the Ministry of Health of Madrid.

“In the Community of Madrid, agreements, subsidies and public bidding are mainly used to improve the Public Health Surveillance System. In fact, as we are immersed in a restructuring process, progress is being made in a series of agreements that allow us to design strategies to implement policies for the development of Public Health actions aimed at promoting Health and prevention in the local environment” , he explained, pointing out that the keys to a prosperous public-private collaboration are the legal securitythe transparency and the evaluation of results.

Although it may contain statements, data or notes from health institutions or professionals, the information contained in Redacción Médica is edited and prepared by journalists. We recommend to the reader that any health-related questions be consulted with a health professional.

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Check Also
Close
Back to top button